このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Maravai LifeSciences Holdings マネジメント

マネジメント基準チェック /44

Maravai LifeSciences Holdings'の CEO はTrey Martinで、 Jul2023年に任命され、の在任期間は 1 年未満です。の年間総報酬は$ 2.30Mで、 32.6%給与と67.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.16%を直接所有しており、その価値は$ 2.78M 。経営陣と取締役会の平均在任期間はそれぞれ2年と3.6年です。

主要情報

Trey Martin

最高経営責任者

US$2.3m

報酬総額

CEO給与比率	32.6%
CEO在任期間	less than a year
CEOの所有権	0.2%
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	3.6yrs

経営陣の近況

Recent updates

RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One

Jun 12

Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

May 14

An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Apr 07

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Feb 28

Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Dec 19

Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Aug 14

Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Feb 28

Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 01

Maravai Lifesciences temporarily reinstates Carl Hull as CEO

Oct 19

Maravai LifeSciences appoints former Danaher executive as CEO

Oct 03

Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M

Aug 04

Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Jun 27

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 29

Maravai Faces Skeptical Investors As Pandemic Enters New Period

Jan 27

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk

Dec 02

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price

Oct 07

CEO報酬分析

Maravai LifeSciences Holdings の収益と比較して、Trey Martin の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$131m
Dec 31 2023	US$2m	US$750k	-US$119m
Sep 30 2023	n/a	n/a	US$25m
Jun 30 2023	n/a	n/a	US$75m
Mar 31 2023	n/a	n/a	US$153m
Dec 31 2022	US$15m	US$660k	US$220m

報酬と市場: Treyの総報酬 ($USD 2.30M ) は、 US市場 ($USD 5.66M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Treyの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Trey Martin (49 yo)

less than a year

在職期間

US$2,301,864

報酬

Mr. William E. Martin, III, also known as Trey, was President of Biologics Safety Testing of Maravai LifeSciences Holdings, Inc. since December 5, 2022 until July 27, 2023 and is its Chief Executive Office...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Carl Hull	Co-Founder & Executive Chairman	3.6yrs	US$5.22m	0.22% $ 4.0m
William Martin	Chief Executive Officer	less than a year	US$2.30m	0.16% $ 2.9m
Kevin Herde	Executive VP & CFO	7.1yrs	US$2.79m	0.022% $ 401.7k
Peter Leddy	Executive VP & Chief Administrative Officer	2yrs	US$2.83m	0.030% $ 542.9k
Christine Dolan	Executive VP & GM of Cygnus Technologies	6.7yrs	US$2.26m	0.020% $ 353.5k
Andrew Burch	President of Nucleic Acid Production	1.3yrs	US$2.99m	0.024% $ 434.0k
Debra Hart	Senior Director of Investor Relations	no data	データなし	データなし
Kurt Oreshack	Executive VP	3.6yrs	US$701.40k	0.019% $ 347.4k
Rebecca Buzzeo	Executive VP & Chief Commercial Officer	1.3yrs	データなし	0.015% $ 267.3k
Kate Broderick	Chief Innovation Officer	1.3yrs	データなし	データなし

2.0yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: MRVIの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Carl Hull	Co-Founder & Executive Chairman	3.6yrs	US$5.22m	0.22% $ 4.0m
John DeFord	Independent Director	less than a year	US$435.03k	データなし
Constantine Mihas	Non-Independent Director	3.6yrs	US$370.48k	0.0032% $ 58.1k
Sean Cunningham	Non-Independent Director	3.6yrs	US$367.98k	0.0032% $ 58.1k
Gregory Lucier	Independent Director	3.6yrs	US$360.48k	0.023% $ 422.6k
Susannah Gray	Independent Director	3.6yrs	US$395.48k	0.027% $ 490.4k
Benjamin Daverman	Non-Independent Director	3.6yrs	US$360.48k	0.0032% $ 58.1k
Luke Marker	Non-Independent Director	3.6yrs	US$360.48k	0.0032% $ 58.1k
Murali Prahalad	Independent Director	3.6yrs	US$367.98k	0.016% $ 282.8k
Jessica Hopfield	Independent Director	3.6yrs	US$387.98k	0.050% $ 897.9k
Anat Ashkenazi	Independent Director	3.6yrs	US$392.98k	0.012% $ 219.0k

3.6yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: MRVIの取締役会は経験豊富であると考えられます ( 3.6年の平均在任期間)。

Maravai LifeSciences Holdings マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 23, 2024

Maravai Lifesciences Holdings, Inc. Appoints William Trey Martin as Chief Executive Officer

Maravai LifeSciences Holdings, Inc. Announces Board Changes

Maravai LifeSciences Holdings, Inc. Announces Executive Changes

High number of new and inexperienced directors

Recent updates

Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024

RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One

Price target increased by 9.3% to US$10.69

Now 23% overvalued after recent price rise

Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Maravai LifeSciences Holdings, Inc., Annual General Meeting, May 23, 2024

Maravai LifeSciences Holdings, Inc. to Report Q1, 2024 Results on May 08, 2024

An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Now 20% undervalued

Consensus EPS estimates fall from profit to US$0.044 loss

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Now 23% undervalued

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Investor sentiment deteriorates as stock falls 17%

Maravai LifeSciences Holdings, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Consensus EPS estimates fall by 230%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 20% to US$10.90

Now 24% undervalued after recent price drop

Maravai LifeSciences Holdings, Inc. Provides Updated Earnings Guidance for the Full Year 2023

Maravai LifeSciences Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 15%

Consensus EPS estimates upgraded to US$0.033 loss

New major risk - Revenue and earnings growth

Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Maravai Lifesciences Holdings, Inc. Provides Earnings Guidance for the Year 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Maravai Lifesciences Holdings, Inc. Appoints William Trey Martin as Chief Executive Officer

Maravai LifeSciences Holdings, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Maravai LifeSciences Holdings, Inc. Announces Board Changes

Consensus EPS estimates fall by 26%

Price target decreased by 8.6% to US$19.36

First quarter 2023 earnings released: US$0.001 loss per share (vs US$0.51 profit in 1Q 2022)

Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Year 2023

Now 22% undervalued

Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.3% to US$21.55

Maravai LifeSciences Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Investor sentiment improved over the past week

Maravai LifeSciences Holdings, Inc. Announces Executive Changes

Price target decreased to US$23.78

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Maravai LifeSciences Holdings, Inc. Provides Revenue Guidance for 2022

Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Investor sentiment deteriorated over the past week

Maravai Lifesciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation

Maravai LifeSciences Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Maravai Lifesciences temporarily reinstates Carl Hull as CEO

Investor sentiment deteriorated over the past week

Maravai LifeSciences Announces CEO Leadership Transition

Maravai LifeSciences appoints former Danaher executive as CEO

Maravai Lifesciences Holdings, Inc. Provides Revenue Guidance for 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M

Maravai LifeSciences Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Maravai LifeSciences, Inc. Appoints Peter Leddy as Executive Vice President and Chief Administrative Officer

Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Investor sentiment deteriorated over the past week

Price target decreased to US$44.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Maravai LifeSciences Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

マネジメント基準チェック /44